Patent intelligence · US
US 11697689
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
Patent details — US 11697689
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 11, 2023
- Expiration
- Jul 6, 2043
- Applicant
- INSTITUT DE CANCEROLOGIE DE L'OUEST
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61P
Quick answer
US 11697689 (Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs) is held by INSTITUT DE CANCEROLOGIE DE L'OUEST. Status: granted. Granted Jul 11, 2023. Expires Jul 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- INSTITUT DE CANCEROLOGIE DE L'OUEST
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61P, A61P35/00, A61P35/02
More from INSTITUT DE CANCEROLOGIE DE L'OUEST
Related pharmaceutical patents in our USPTO index.
-
US 12303551
Cellular immunotherapy compositions and uses thereof
granted -
US 12291557
Chimeric TIM4 receptors and uses thereof
granted -
US 11708423
Chimeric engulfment receptor molecules and methods of use
granted -
US 11655282
Chimeric engulfment receptor molecules
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10307410
Mcl-1 modulating compounds for cancer treatment
granted -
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
granted
Frequently asked questions
What is US patent 11697689?
US 11697689 (Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs) is held by INSTITUT DE CANCEROLOGIE DE L'OUEST. Status: granted. Granted Jul 11, 2023. Expires Jul 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11697689?
INSTITUT DE CANCEROLOGIE DE L'OUEST is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11697689 expire?
Our index shows an expiration date of Jul 6, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.